IMMUNOVANT, INC. (IMVT) Free cash flow 2019–2026
IMMUNOVANT, INC. (IMVT) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$407.3MFY2026 · since FY2019: -$28.6M → -$407.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$407.3M | -8.1% |
| FY2025 | -$376.6M | -75.5% |
| FY2024 | -$214.6M | -13.9% |
| FY2023 | -$188.4M | -77.1% |
| FY2022 | -$106.4M | -27.3% |
| FY2021 | -$83.5M | -56.5% |
| FY2020 | -$53.4M | -86.7% |
| FY2019 | -$28.6M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More IMVT financial trends
IMVT RevenueIMVT Net incomeIMVT Net marginIMVT Gross profitIMVT Gross marginIMVT Operating incomeIMVT Operating marginIMVT Operating cash flowIMVT Capital expendituresIMVT Return on equityIMVT Stock buybacksIMVT Dividends paidIMVT Total assetsIMVT Total liabilitiesIMVT Shareholders’ equityIMVT overview →